Safety, Tolerability and Efficacy of Enhanced IL-13Rα2 Targeted Chimeric Antigen Receptor T Cell Immunotherapy Against Recurrent/Refractory Grade 4 Glioma
Safety, Tolerability and Efficacy of Enhanced IL-13Rα2 Targeted Chimeric Antigen Receptor T Cell Immunotherapy Against Recurrent/Refractory Grade 4 Glioma is a PHASE1 clinical asset sponsored by Yang Zhang in Glioma. SEO and diligence focus: IL13Rα2 CAR-T, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Indication: Glioma
Modality: cell therapy
Target: IL13Rα2 CAR-T
Sponsor: Yang Zhang
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 28, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: IL13Rα2 CAR-T
View original source fields
Condition raw: Glioma
Condition normalized: Glioma
Modality raw: cell therapy
Modality normalized: cell therapy
Target raw: IL13Rα2 CAR-T
Target normalized: IL13Rα2 CAR-T